1.
Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Li, Y, Li, S, Zhu, Y, Liang, X, Meng, H, Chen, J, Zhang, D, Guo, H, Shi, B
Journal of clinical hypertension (Greenwich, Conn.). 2014;(3):177-85
-
-
Free full text
-
Abstract
Hypertension is one of the major side effects of sorafenib, and reported incidences vary substantially among clinical trials. A systematic review was conducted using Medline, PubMed, Embase, and the Cochrane Library for all longitudinal studies to investigate the incidence and risk of hypertension events in cancer patients treated with sorafenib. A total of 14 randomized controlled trials and 39 prospective single-arm trials involving 13,555 patients were selected for the meta-analysis. The relative risk of all-grade and high-grade hypertension associated with sorafenib were 3.07 (95% confidence interval [CI], 2.05–4.60; P<.01) and 3.31 (95% CI, 2.21–4.95; P<.01), respectively. The overall incidence of sorafenib-induced all-grade and high-grade hypertension were 19.1% (95% CI, 15.8%–22.4%) and 4.3% (95% CI, 3.0%–5.5%), respectively. A significantly higher incidence of hypertension was noted in patients with renal cell carcinoma (RCC) compared with those with non-RCC malignancies (all-grade: 24.9% [95% CI, 19.7%–30.1%] vs 15.7%[95% CI, 12.1%–19.3%]; P<.05; high-grade:8.6% [95% CI, 6.0%–11.2%] vs 1.8% [95% CI, 0.9%–2.6%]; P<.05). The trials with median progression-free survival (PFS) longer than 5.3 months (mean PFS) demonstrated a significantly higher incidence of high-grade hypertension than trials with shorter PFS (6.3% [95% CI, 4.1%–8.5%] vs 2.6% [95% CI, 1.4%– 3.8%]; P<.05). Findings of the meta-analysis indicated a significantly high risk of sorafenib-induced hypertension. Patients with RCC have a significantly higher incidence of hypertension and the occurrence of hypertension may be associated with improved prognosis.
2.
Technologies for deriving primary tumor cells for use in personalized cancer therapy.
Mitra, A, Mishra, L, Li, S
Trends in biotechnology. 2013;(6):347-54
-
-
Free full text
-
Abstract
For decades, immortal cancer cell lines have constituted an accessible, easily usable set of biological models to investigate cancer biology and explore the potential efficacy of anticancer drugs. However, numerous studies have suggested that these cell lines poorly represent the diversity, heterogeneity, and drug-resistant tumors occurring in patients. The derivation and short-term culture of primary cells from solid tumors have thus gained significant importance in personalized cancer therapy. This review focuses on our current understanding and the pros and cons of different methods for primary tumor cell culture. Furthermore, various culture matrices such as biomimetic scaffolds and chemically defined media supplemented with essential nutrients, have been prepared for different tissues. These well-characterized primary tumor cells redefine cancer therapies with high translational relevance.